Trade Report: Today, DUPONT CAPITAL MANAGEMENT Corp Takes Position in Insys Therapeutics Inc. (INSY)

Today, DUPONT CAPITAL MANAGEMENT Corp Takes Position in Insys Therapeutics Inc. (INSY)

DUPONT CAPITAL MANAGEMENT Corp bought a new stake in Insys Therapeutics Inc. (NASDAQ:INSY) during the third quarter, according to its most recent filing with the SEC. The fund bought 36,606 shares of the specialty pharmaceutical company’s stock, valued at approximately $432,000. DUPONT CAPITAL MANAGEMENT Corp owned approximately 0.05% of Insys Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Folger Hill Asset Management LP boosted its stake in Insys Therapeutics by 11.4% in the second quarter. Folger Hill Asset Management LP now owns 1,597,945 shares of the specialty pharmaceutical company’s stock valued at $20,677,000 after buying an additional 163,107 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Insys Therapeutics by 5.9% in the first quarter. BlackRock Fund Advisors now owns 1,498,868 shares of the specialty pharmaceutical company’s stock valued at $23,967,000 after buying an additional 83,040 shares during the last quarter. HealthInvest Partners AB purchased a new stake in Insys Therapeutics during the second quarter valued at approximately $10,199,000. BlackRock Institutional Trust Company N.A. boosted its stake in Insys Therapeutics by 9.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 644,914 shares of the specialty pharmaceutical company’s stock valued at $8,345,000 after buying an additional 56,484 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Insys Therapeutics by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 506,159 shares of the specialty pharmaceutical company’s stock valued at $6,550,000 after buying an additional 20,446 shares during the last quarter. 47.12% of the stock is owned by hedge funds and other institutional investors.

Shares of Insys Therapeutics Inc. (NASDAQ:INSY) traded up 3.86% during trading on Friday, hitting $13.20. 391,718 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $12.04 and its 200 day moving average is $14.05. The firm has a market capitalization of $947.36 million, a PE ratio of 42.17 and a beta of 0.94. Insys Therapeutics Inc. has a 1-year low of $10.01 and a 1-year high of $33.88.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The firm had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.97 million. Insys Therapeutics had a net margin of 8.71% and a return on equity of 9.39%. The business’s revenue was down 39.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.50 EPS. On average, equities research analysts forecast that Insys Therapeutics Inc. will post $0.34 earnings per share for the current year.

INSY has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 9th. Royal Bank Of Canada lowered their target price on shares of Insys Therapeutics from $32.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, September 22nd. RBC Capital Markets reaffirmed a “sector perform” rating and issued a $23.00 target price (down from $26.00) on shares of Insys Therapeutics in a research note on Friday, November 4th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, November 6th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $22.00 target price (up from $17.00) on shares of Insys Therapeutics in a research note on Thursday, August 4th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $23.00.

In related news, Director Steven J. Meyer purchased 10,000 shares of the stock in a transaction on Friday, November 4th. The shares were purchased at an average cost of $10.75 per share, with a total value of $107,500.00. Following the acquisition, the director now directly owns 44,083 shares in the company, valued at $473,892.25. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 69.20% of the stock is currently owned by company insiders.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Related posts

Leave a Comment